1
|
Savioli F, Morrow ES, Cheung LK, Stallard S, Doughty J, Romics L. Routine four-quadrant cavity shaving at the time of wide local excision for breast cancer reduces re-excision rate. Ann R Coll Surg Engl 2023; 105:56-61. [PMID: 35174724 PMCID: PMC9773244 DOI: 10.1308/rcsann.2021.0285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2022] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION Breast conservation therapy (BCT) has been shown to have comparable long-term survival outcomes when compared with mastectomy. Clearance of excision margin is one of the mainstays of the surgical treatment, which if not achieved at the first operation of BCT results in the need for subsequent surgery. METHODS This study evaluated the impact of routinely taken cavity shavings on re-excision rates. This retrospective two-centre study describes the use of routine four-quadrant cavity shaving in 449 patients with consecutively treated with wide local excision for invasive cancer or ductal carcinoma in situ. RESULTS The overall incomplete excision rate was 10.6%. Routine cavity shaving prevented the need for re-excision in 84 patients (18.7%) and identified the need for further re-excision in 33 patients (7.3%). Median time from surgery to radiotherapy was 50 days (range 13-209) for non-re-excised patients versus 78 days (range 47-260) for re-excised patients (p<0.001). Median time to chemotherapy (n=75) was 44 days (range 14-106) for non-re-excised patients versus 56 days (range 35-116) for re-excised patients (p=0.017). CONCLUSIONS This study demonstrates that routine cavity shaving decreases re-excision rate in patients treated with wide local excision and prevents delays to adjuvant treatment due to incomplete excision.
Collapse
MESH Headings
- Humans
- Female
- Breast Neoplasms/pathology
- Retrospective Studies
- Mastectomy
- Carcinoma, Intraductal, Noninfiltrating/surgery
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Mastectomy, Segmental/methods
- Reoperation
- Neoplasm Recurrence, Local/epidemiology
- Neoplasm Recurrence, Local/prevention & control
- Neoplasm Recurrence, Local/pathology
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Ductal, Breast/pathology
Collapse
Affiliation(s)
| | | | - LK Cheung
- Swansea Bay University Health Board, UK
| | | | | | | |
Collapse
|
2
|
Edwards J, McMillan D, Stallard S, Doughty J, Romics L, Savioli F. The effect of postoperative complications on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30826-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
Savioli F, Edwards J, McMillan D, Stallard S, Doughty J, Romics L. The effect of postoperative complications on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020; 155:103075. [PMID: 32987333 DOI: 10.1016/j.critrevonc.2020.103075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Accepted: 08/03/2020] [Indexed: 10/23/2022] Open
Abstract
BACKGROUND This systematic review investigated the impact of complications on long term outcomes for patients with primary invasive operable breast cancer. METHODS A systematic review was performed using appropriate keywords, and meta-analysis using a random effects model completed. RESULTS Ten retrospective cohort studies, including 37,657 patients were included. Five studies identified a relationship between wound complications, infection and pyrexia and recurrence or recurrence-free survival. Risk of recurrence, 1-year and 5-year recurrence-free survival and overall survival were related to complications, particularly for patients with poor Nottingham Prognostic Index. Five studies failed to demonstrate a relationship between complications and prognosis. Complication was found to significantly affect 5-year recurrence-free survival (HR 1.48 95 % CI 1.02-2.14, p = 0.04) but not recurrence (HR 2.39, 95 %CI 0.94-6.07, p = 0.07), with a high degree of heterogeneity amongst analysed studies (I2 = 95 %). DISCUSSION Further research is needed to quantify the effects of postoperative complication on prognosis following surgery for breast cancer.
Collapse
Affiliation(s)
- F Savioli
- Clinical Research Fellow, Specialty Trainee (General Surgery), Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Level 2 New Lister Building, Glasgow Royal Infirmary, 8-16 Alexandra Parade, Glasgow G31 2ER, United Kingdom.
| | - J Edwards
- Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1QH, United Kingdom
| | - D McMillan
- Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Level 2 New Lister Building, Glasgow Royal Infirmary, 8-16 Alexandra Parade, Glasgow G31 2ER, United Kingdom
| | - S Stallard
- Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom
| | - J Doughty
- Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom
| | - L Romics
- New Victoria Hospital, 52 Grange Road, Glasgow G42 9LF, United Kingdom; Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Level 2 New Lister Building, Glasgow Royal Infirmary, 8-16 Alexandra Parade, Glasgow G31 2ER, United Kingdom
| |
Collapse
|
4
|
Morrow E, Lannigan A, Doughty J, Litherland J, Mansell J, Stallard S, Mallon E, Romics L. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. Br J Surg 2018; 105:987-995. [PMID: 29623677 DOI: 10.1002/bjs.10791] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 08/12/2017] [Accepted: 11/12/2017] [Indexed: 01/13/2023]
Abstract
BACKGROUND Preoperative staging of the axilla is important to allow decisions regarding neoadjuvant treatment and the management of the axilla. Invasive lobular carcinoma metastases are difficult to detect because of the infiltrative pattern of the nodal spread. In this study the sensitivity of preoperative axillary staging between invasive lobular (ILC) and ductal (IDC) carcinoma was compared. METHODS All women diagnosed with pure ILC or IDC in the West of Scotland in 2012-2014 were identified from a database maintained prospectively within the Managed Clinical Network. Pretreatment axillary ultrasound imaging (AUS), core biopsy and fine-needle aspiration cytology (FNAC) results were compared between ILC and IDC. RESULTS Some 602 women with ILC and 4199 with IDC had undergone axillary surgery, of whom 209 and 1402 respectively had nodal metastases. Pretreatment AUS sensitivity was significantly lower in ILC than in IDC (32·1 versus 50·1 per cent respectively, P < 0·001; OR 0·47, 95 per cent c.i. 0·34 to 0·64). Core biopsy had equally high sensitivity of 86 per cent in both subtypes; however, FNAC was significantly less sensitive in both ILC (55 per cent; P = 0·003) and IDC (75·6 per cent; P = 0·006). Multivariable analysis revealed that cT3-4 status and symptomatic presentation were both significant in predicting nodal metastasis in patients with ILC and false-negative AUS findings (OR 3·77, 95 per cent c.i. 1·69 to 8·42, P = 0·001; and OR 1·92, 1·24 to 2·98, P = 0·003, respectively). CONCLUSION AUS is inferior in detecting axillary node metastasis in ILC compared with IDC. Women with cT3-4 lobular carcinoma may benefit from ultrasound-guided axillary biopsy regardless of the ultrasonographic appearance of the nodes.
Collapse
Affiliation(s)
- E Morrow
- Department of Academic Surgery, University of Glasgow, Glasgow, UK
| | - A Lannigan
- Department of Surgery, Wishaw General Hospital, Wishaw, UK
| | - J Doughty
- Department of Surgery, Gartnavel General Hospital, Glasgow, UK
| | - J Litherland
- Department of Radiology, West of Scotland Breast Screening Centre, Glasgow, UK
| | - J Mansell
- Department of Surgery, Wishaw General Hospital, Wishaw, UK
| | - S Stallard
- Department of Surgery, Gartnavel General Hospital, Glasgow, UK
| | - E Mallon
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
| | - L Romics
- Department of Academic Surgery, University of Glasgow, Glasgow, UK.,Department of Surgery, New Victoria Hospital, Glasgow, UK
| |
Collapse
|
5
|
Romics L, Macaskill J, Fernandez T, Morrow E, Simpson L, Pitsinis V, Barber M, Tovey S, Masannat Y, Young O, Mansell J, Stallard S, Doughty J, Dixon M. Abstract P4-13-01: Oncoplastic breast conservations – The Scottish Audit: Surgical techniques, oncological outcomes, complication rates and variations in practice across the country based on the analysis of 589 patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: current evidence for oncoplastic breast conservation (OBC) is based on single institutional series. We studied the outcomes of OBC practice in Scotland and compare individual breast units.
Methods: a predefined database of patients treated with OBC was completed retrospectively in 11 breast units in Scotland. Patients were treated with OBC from 2005 onwards were included. For statistical calculations Chi-test, ANOVA and Pearson correlation analysis were used.
Results: Altogether 589 patients were included. Median age was 56 years [21-86]. Patients were diagnosed between September 2005 and March 2017. Number of patients treated with OBC per unit ranged between 4 and 145. High volume units were doing a mean of 19.3 OBCs per year [17.3 – 26.5] vs. low volume units doing 11.1 OBCs per year [7 .7– 14.4] (p=0.012).
23 different oncoplastic surgical techniques were applied. Range of oncoplastic techniques used was associated with case-loads: high volume units used a wider range (8 – 14 different techniques) compared to low volume units (3 – 6) (p=0.004). Volume displacement was done in 515 patients (91.3%), volume replacement in 49 patients (8.7%). OBC was carried out as a joint operation between a breast and a plastic surgeon in 66.3% (389 patients). Immediate contralateral symmetrisation rate was significantly higher when the procedure was carried out as a joint operation (70.7% vs. not joint operations: 29.8%; p<0.001).
Incomplete excision rate was 10.4% (60 of 578). Incomplete excision was significantly higher after invasive lobular carcinoma (18.9%; 10 of 43; p=0.0292). After neoadjuvant chemotherapy incomplete excision rate was significantly lower (3%; 2 of 66 vs. no neoadjuvant chemotherapy: 11%; 35 of 319; p=0.031).
Neodjuvant systemic treatment rate was 28.6% (142 of 496 patients). Of those 68 patients received neoadjuvant chemotherapy (13.7%) and 74 patients had neoadjuvant hormonal treatment (14.9%). Neoadjuvant systemic treatment rate varied amongst the units from 9.7% to 57.2% for patients with invasive carcinoma.
259 patients diagnosed with (non)invasive carcinoma had a median follow-up time of 5 years [35-124]. Of these 7 patients (2.7%) developed isolated local recurrence. 5-year local recurrence rate after DCIS was higher than after pure invasive ductal carcinoma (DCIS: 8.3%; 3 of 36 vs. ductal: 1.6%; 3 of 181; p=0.02567). 5-year disease-free survival of these patients was 91.7%, overall survival was 93.8%, and cancer-specific survival was 96.1%.
145 of 510 patients developed complications, which is 28.4% overall complication rate. 71 patients had major complications (13.9%) and 74 patients had minor complications (14.5%). Overall complication rate was significantly lower after neoadjuvant chemotherapy (15.9%; 11 of 69) compared to patients who did not receive neoadjuvant chemotherapy (27.9%; 127 of 455 patients) (p=0.035).
Conclusion: this national audit demonstrated similar outcomes overall compared to relevant published data. Units should be urged to build stronger collaboration in order to reduce variability in OBC practices.
None of the authors have conflict of interest to declare.
Citation Format: Romics L, Macaskill J, Fernandez T, Morrow E, Simpson L, Pitsinis V, Barber M, Tovey S, Masannat Y, Young O, Mansell J, Stallard S, Doughty J, Dixon M. Oncoplastic breast conservations – The Scottish Audit: Surgical techniques, oncological outcomes, complication rates and variations in practice across the country based on the analysis of 589 patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-01.
Collapse
Affiliation(s)
- L Romics
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - J Macaskill
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - T Fernandez
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - E Morrow
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - L Simpson
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - V Pitsinis
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - M Barber
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - S Tovey
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - Y Masannat
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - O Young
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - J Mansell
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - S Stallard
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - J Doughty
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| | - M Dixon
- New Victoria Hospital Glasgow, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Glasgow, United Kingdom; Aberdeen Royal Infirmary, United Kingdom; University Hospital Crosshouse, Ayrshire, United Kingdom; Wishaw General Hospital, Lanarkshire, United Kingdom; Gartnavel General Hospital, Glasgow, United Kingdom; New Stobhill Hospital, Glasgow, United Kingdom
| |
Collapse
|
6
|
Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast 2017; 32:179-185. [PMID: 28214785 DOI: 10.1016/j.breast.2017.02.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 01/30/2017] [Accepted: 02/08/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Support for the oncological safety of oncoplastic breast conservation surgery (OBCS) is mostly based on evidence comparing recurrence rates after OBCS to wide local excision (WLE). However, OBCS is often indicated for larger cancers and oncological results should also be compared to patients treated with mastectomy. In this study we compared recurrence and survival following OBCS, mastectomy and WLE. METHODS Patients treated with OBCS between 2009 and 2012 were identified from a prospectively maintained database. For comparison, consecutive patients treated with WLE or mastectomy with or without immediate reconstruction (Ms ± IR) over the same time period were identified. Histological variables of patients were compared using Fisher Exact or Chi squared tests, and recurrence and survival were compared using Kaplan-Meier and Cox regression survival analysis. RESULTS 980 patients' data were analysed (OBCS: n = 104; WLE: n = 558; Ms ± IR: n = 318). Tumour size, grade, nodal status, ER, and PR expression of patients treated with OBCS were all significantly more adverse compared with patients treated with WLE (p < 0.001). These histological variables were similar in patients treated with Ms ± IR and OBCS. 5-year local recurrence rates were similar in all three groups (WLE: 3.4 per cent, OBCS: 2 per cent, Ms ± IR: 2.6 per cent; log rank = 0.973), while distant recurrence rates were higher after Ms ± IR and OBCS (Ms ± IR:13.1 per cent, OBCS:7.5 per cent, WLE:3.3 per cent; log rank: p < 0.001). CONCLUSION OBCS is oncologically safe in patients even when histological results are similar to patients treated with Ms ± IR.
Collapse
Affiliation(s)
- J Mansell
- Department of Surgery, New Victoria Hospital Glasgow, UK
| | | | - S Stallard
- Department of Surgery, Gartnavel General Hospital Glasgow, UK
| | - J C Doughty
- Department of Surgery, Gartnavel General Hospital Glasgow, UK
| | - E Mallon
- Department of Pathology, Queen Elizabeth University Hospital, UK
| | - L Romics
- Department of Surgery, New Victoria Hospital Glasgow, UK; Department of Surgery, Gartnavel General Hospital Glasgow, UK.
| |
Collapse
|
7
|
Romics L, Kabir SA, Mansell J, Mallon EA, Stallard S, Doughty JC. Abstract P2-12-14: Therapeutic mammoplasty reduces high incomplete excision rate in lobular cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-12-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Incomplete excision rate for lobular cancer is much higher compared to other types of breast cancer, since lobular cancer is frequently occult on imaging. This, and the inability to downstage lobular cancer with neoadjuvant therapy lead to the highest mastectomy rate of all subtypes. Here, we investigated the association between histopathological characteristics and incomplete excision as well as mastectomy rates.
Further, we investigated whether the application of level 2 therapeutic mammoplasty (TM) would extend the indication for conservation with lobular cancers.
Methods: Data of 1389 consecutive patients underwent surgery for (non)invasive breast cancer between January 2008 and June 2012 was analysed. Pathological and preoperative radiological results were analysed in the context of final surgery and tumour excision margins. Statistical significance was calculated using Chi-square, Mann-Whitney and Z-tests with a significance<0.05.
Results: Overall incomplete excision rate was 13.74% (131/953), and mastectomy rate was 35.35% (491/1389). Higher incomplete excision and mastectomy rates were strongly associated with lobular subtype (IE: 26.03% (19/73)); M: 51.22% (63/123); p<0.01 vs. other subtypes), node positivity (IE: 25% (36/144) vs. 10.43% (68/652); p=0 and M: 60.69% (193/318) vs. 25.65% (216/842); p=0) and tumour size (IE:T3 80% (4/5) vs. T2 22.51% (43/191) vs. T1 9.23% (55/596); all p<0.01; and M: T3 95.35% (41/43) vs. 59.46% (242/407) vs. 16.16% (112/693); all p=0). Incomplete excision rates were independent of hormonal and HER-2 expressions (ER+: 12.55% (89/709) vs. ER-: 16.67% (15/90); p=0.27 and HER2 neg.: 12.67% (91/718) vs. HER2 pos.: 16.67% (13/78); p=0.32) and it was just higher in grade 2 and 3 cancers (14.6% (60/411); p=0.037 and 16.22% (36/222); p=0.021 vs. G1:6.86% (7/102). However, hormonal and HER-2 expressions as well as tumour grade were in strong association with mastectomy rate (ER pos.: 33.28% (335/1007) vs. ER neg.: 48.75% (78/160); p<0.01; HER2 neg.: 33.43% (341/1020) vs. HER2 pos.: 49.65% (71/143); p<0.01; G3: 50.49% (205/406) vs. G2: 30.77%(172/559) vs. G1: 14.28% (17/119); all p=0).
135 patients underwent surgery for lobular cancer (simple wide excision: 66; TM:19; mastectomy: 50). TM was offered for significantly larger tumours than lumpectomy (28.29mm (10-62) vs. 19.96mm(5-57);p<0.01; vs. mastectomy: 37.56 mm(5-110);p=0.096). Incomplete margins were found with significantly smaller tumours when lumpectomy was applied compared to TM(25.94 mm(6-56) vs. 38.6 mm(30-45);p=0.031). Conservation was achieved with significantly bigger tumours when TM was used (25.46mm (10-62) vs. 17.66mm (5-57); p=0.032). Multifocality, however, significantly increased the chance for incomplete excision even after TM (4/7; p=0.019).
Conclusion: Higher incomplete excision rate is strongly associated with lobular subtype, node positivity and tumour size, but independent of hormonal end HER-2 expression, while tumour grade is not a strong predictor. All histopathological characteristics are strong predictors of final mastectomy rate. Using TM, breast conservation can be achieved for significantly larger lobular cancers, and incomplete excision rate decreased in smaller cancers, which are routinely treated with wide excision.
Citation Format: Romics L, Kabir SA, Mansell J, Mallon EA, Stallard S, Doughty JC. Therapeutic mammoplasty reduces high incomplete excision rate in lobular cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-12-14.
Collapse
Affiliation(s)
- L Romics
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| | - SA Kabir
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| | - J Mansell
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| | - EA Mallon
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| | - S Stallard
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| | - JC Doughty
- Victoria Infirmary Glasgow, Glasgow, United Kingdom; Royal Infirmary Glasgow, Glasgow, United Kingdom; New Southern University Hospital Glasgow, Glasgow, United Kingdom; Western Infirmary Glasgow, Glasgow, United Kingdom
| |
Collapse
|
8
|
Mansell J, Weiler-Mithoff E, Martin J, Khan A, Stallard S, Doughty JC, Romics L. How to compare the oncological safety of oncoplastic breast conservation surgery - To wide local excision or mastectomy? Breast 2015; 24:497-501. [PMID: 26009307 DOI: 10.1016/j.breast.2015.05.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 04/13/2015] [Accepted: 05/03/2015] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Comparative studies suggest that patients treated with oncoplastic breast conservation surgery (OBCS) have similar pathology to patients treated with wide local excision (WLE). However, patients treated with OBCS have never been compared to patients treated with mastectomy. The aim of this study was to identify which control group was comparable to patients undergoing OBCS. METHODS Commonly reported histopathological variables of patients treated with OBCS, WLE or mastectomy ± immediate reconstruction (Ms ± IR) were compared using Fisher Exact or Chi squared tests. RESULTS 1000 patients' data were analysed (OBCS: n = 119; WLE: n = 600; Ms ± IR: n = 281). Tumour size was significantly bigger after OBCS than WLE (p < 0.001), but similar to Ms ± IR (p = 0.138). Tumour grade was higher after OBCS than WLE (p < 0.001), but similar to Ms ± IR (p = 0.497). More axillary nodes were involved in patients with OBCS than WLE (p < 0.001), but comparable to Ms ± IR (p = 0.175). ER and PR expressions were lower after OBCS compared to WLE (p = 0.007, p = 0.009), but identical to Ms ± IR (p = 1, p = 0.904 respectively). Differences in application of systemic (neo)adjuvant therapy followed the above trend. CONCLUSION Striking similarities found between OBCS and mastectomy patients' histopathological results are in sharp contrast with previously published data. This study suggests that oncological outcomes following OBCS should be compared to mastectomy besides WLE.
Collapse
Affiliation(s)
- J Mansell
- Department of Surgery, Victoria Infirmary Glasgow, UK
| | | | - J Martin
- Department of Surgery, Victoria Infirmary Glasgow, UK
| | - A Khan
- Department of Surgery, Victoria Infirmary Glasgow, UK
| | - S Stallard
- Department of Surgery, Western Infirmary Glasgow, UK
| | - J C Doughty
- Department of Surgery, Western Infirmary Glasgow, UK
| | - L Romics
- Department of Surgery, Victoria Infirmary Glasgow, UK.
| |
Collapse
|
9
|
Mansell J, Martin J, Khan A, Weiler-Mithoff E, Stallard S, Doughty JC, Romics L. Abstract P5-15-07: Therapeutic mammaplasty - Radical breast conservation or conservative mastectomy? A comperative analysis of 1000 patients’ pathology results. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-15-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: oncological principles of therapeutic mammaplasty (TM) is based on evidence arising from studies on the oncological safety of traditional breast conservation, i.e. wide local excision (WLE). Hence, oncological safety of TM is benchmarked to patients treated with WLE. However, TM can also be defined as a conversion of mastectomy (Ms) to breast conservation surgery applying plastic surgical techniques in patients conventionally requiring mastectomy. The aim of this study was to decide if TM was similar to WLE or Mx in terms of pathological characteristics.
Methods: 1006 consequtive patients were involved in the analysis, who were treated with TM, WLE or Ms in two Glasgow breast units between 2008 and 2011. Histopathological characteristics of patients treated with TM were compared to those treated with WLE or Ms. Statistical calculations were carried out with Chi-square test. The difference was considered statistically significant if p>0.05.
Results: 121 patients were treated with TM, while 600 patients were treated with WLE and 285 with Ms. Tumour size of TM was significantly different from WLE as well as Ms, although the difference between TM and WLE was more significant than between TM and Ms (TM/Ms/WLE: T1: 43.8%, 34%, 78%; T2: 52.1%, 54.7%, 21%; T3: 4.1%, 11.2%, 1%; TM vs. WLE: p<0.001; vs. Ms: p = 0.03). Tumour grade of TM was significantly higher than grade of WLE, but there was no significant difference between the grades of TM and Ms (TM/Ms/WLE: G1: 6.4%, 4.5%, 19.3%; G2: 37.6%, 41.8%, 54.8%; G3: 56%, 53.7%, 26%; TM vs. SZE: p<0.001; vs. Ms: p = 0.625). Similarly, significantly more axillary nodes were involved in patients treated with TM compared to patients with WLE, while the same was comparable in patients with TM and Ms (TM/Ms/WLE: 0: 73.5%, 70.4%, 87.7%; 1-3: 24.5%, 25.6%, 12.2%; >3: 2%, 4%, 0.2%; TM vs. WLE: p<0.001; vs. Ms: p = 0.601). In terms of histological subtypes, again, there was a significant difference between TM and WLE, but we found no difference when TM was compared to Ms (TM vs. WLE: p = 0.027; vs. Ms: p = 0.582). There was statistically significantly more ER and/or PR positive patients in the group treated with WLE compared to TM (ER/PR TM vs. WLE p = 0.012 / = 0.014), but ER/PR expression was similar in TM and Ms patients (ER/PR TM vs. Ms p = 0.890 / = 0.635). While the trend above was similar in HER-2 expression pattern, there was no statistically significant difference could be demonstrated in between the groups (table).
Discussion: pathological characteristics of patients treated with therapeutic mammaplasty is similar to patients treated with mastectomy, but significantly different from patients who were treated with WLE. Pathology after WLE is significantly more favourable compared to TM. Hence, studies investigating oncological safety of TM comparing to patients treated with WLE only may not be adequate, and Ms patients should be included in the analyses.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-15-07.
Collapse
Affiliation(s)
- J Mansell
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - J Martin
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - A Khan
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - E Weiler-Mithoff
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - S Stallard
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - JC Doughty
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - L Romics
- Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| |
Collapse
|
10
|
Schaverien MV, Stallard S, Dodwell D, Doughty JC. Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. Eur J Surg Oncol 2013; 39:1179-85. [PMID: 23988230 DOI: 10.1016/j.ejso.2013.07.240] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 07/10/2013] [Accepted: 07/29/2013] [Indexed: 10/26/2022] Open
Abstract
BACKGROUND The use of local boost radiotherapy to the tumour bed has been demonstrated in randomised-controlled trials to reduce local recurrence rates following breast-conserving surgery (BCS) and is the standard of care. Oncoplastic BCS techniques with parenchymal rearrangement present new challenges to the localisation of the tumour bed and therefore delivery of local boost radiotherapy. The aim of this review was to evaluate the reporting of boost radiotherapy in the oncoplastic BCS literature. METHODS Pubmed, Ovid MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched for studies reporting oncoplastic BCS using volume displacement techniques. RESULTS 24 studies met the inclusion criteria (n = 1933 patients). Use of boost radiotherapy was reported in 11 studies, in 2 of which it was for the treatment of incomplete or close margins, and marking of the tumour bed was only reported in 8 studies. None of the studies reported the number of patients where the tumour bed could not be localised. CONCLUSIONS The use of local boost radiotherapy and tumour bed marking was not reported in the majority of studies of oncoplastic BCS. Future studies need to provide detailed information regarding the use of boost radiotherapy and difficulties determining the target volume so that current radiotherapy approaches can be reviewed and improved for these advanced techniques.
Collapse
Affiliation(s)
- M V Schaverien
- Department of Surgery, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK; Canniesburn Plastic Surgery Unit Jubilee Building, Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK.
| | | | | | | |
Collapse
|
11
|
Khan J, Barrett S, Forte C, Stallard S, Weiler-Mithoff E, Doughty JC, Romics L. Oncoplastic breast conservation does not lead to a delay in the commencement of adjuvant chemotherapy in breast cancer patients. Eur J Surg Oncol 2013; 39:887-91. [PMID: 23746877 DOI: 10.1016/j.ejso.2013.05.005] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Revised: 04/11/2013] [Accepted: 05/08/2013] [Indexed: 01/10/2023] Open
Abstract
INTRODUCTION There is hardly any evidence that oncoplastic breast conservation surgery (OBCS) does not lead to a delay in the commencement of adjuvant chemotherapy. Although this is an integral part of overall oncological safety, no controlled studies have been published so far. Therefore, our aim was to determine whether OBCS led to a delay when compared to simple wide local excision (WLE), mastectomy (Ms) or mastectomy with immediate reconstruction (MsIR). METHODS Breast cancer patients who required adjuvant chemotherapy after OBCS, WLE, Ms and MsIR were identified from prospectively maintained institutional databases. Time between multidisciplinary team decision to offer chemotherapy and delivery of first cycle of chemotherapy was measured and compared among the four groups of patients. RESULTS time to chemotherapy of breast cancer patients (n = 169) treated with OBCS (n = 31) were 29 [16-58] days, while it was 29.5 [15-105] days after WLE (n = 66), 29 [15-57] days after Ms (n = 56) and 31 [15-58] days after MsIR (n = 16). A combined analysis involving all four groups demonstrated no statistically significant difference (p = 0.524). Similarly, inter-group analysis revealed no significant differences in between patients treated with OBCS compared to any of the three control groups (OBCS to WLE: p = 0.433; OBCS to Ms: p = 0.800; OBCS to MsIR: p = 0.405). CONCLUSION OBCS seems as safe as WLE, Ms or MsIR in terms of delivery of adjuvant chemotherapy, and, therefore, should not adversely affect breast cancer outcome in this respect.
Collapse
|
12
|
Khan J, Barrett S, Stallard S, Forte C, Weiler-Mithoff E, Reid I, Winter A, Doughty J, Romics L. Abstract P4-14-13: Therapeutic mammaplasty does not cause a delay in the delivery of chemotherapy in high risk breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-14-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: oncosurgical safety of therapeutic mammaplasty (TM) is widely investigated. The interval between surgery and delivery of adjuvant chemotherapy is an integral part of overall oncological safety. Therefore, we examined the time between TM and AC, and compared it to wide local excision (WLE) and mastectomy (Mx) with or without immediate breast reconstruction (IBR), respectively.
Methods: data of 174 patients who underwent TM, WLE and Mx±IBR was analyzed retrospectively. All patients were operated within three breast units of Glasgow during a period of 48 months. Time between decision to offer adjuvant chemotherpay and delivery of the first cycle of chemotherapy was analyzed. Significance was calculated with Mann-Whitney and Kruskal-Wallis tests (two and four groups compared, respectively).
Results: median time to adjuvant chemotherapy after TM (n = 36) was 29 [16–58] days, WLE (n = 66) was 29.5 [15–105], Mx only (n = 56) was 29 [15–57], and Mx and IBR (n = 16) was 31 [15–58] days. No significant difference was found in terms of time to adjuvant chemotherpay in patients treated with TM compared to WLE (p = 0.384), Mx only (p = 0.828) or Mx and IBR (p = 0.366). Further, there was no significant difference when a cumulative comparison of the four groups was carried out (p = 0.507).
Conclusions: our data indicate that oncosurgical safety of TM in terms of time to chemotherapy is similar to other high risk breast cancer patients treated WLE and Mx with or without IBR. This also suggests that there is no significant difference in postoperative complication rates after these four ways of surgical treatment of breast cancer, which would possibly be the primary cause for a delay in delivering adjuvant chemotherapy.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-14-13.
Collapse
Affiliation(s)
- J Khan
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - S Barrett
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - S Stallard
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - C Forte
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - E Weiler-Mithoff
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - I Reid
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - A Winter
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - J Doughty
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| | - L Romics
- Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom
| |
Collapse
|
13
|
Romics L, Chew B, Stallard S, Doughty J, Weiler-Mithoff E. 565 Does Immediate Breast Reconstruction Technique Influence True Local Recurrence Rate After Skin-sparing Mastectomy? Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70630-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Chakrabarti M, Fitzgerald C, Obondo C, Weiler-Mithoff E, Reid I, Stallard S, Romics L. 533 Patient Counselling and Socioeconomic Deprivation – Two Factors That Profoundly Influence Immediate Breast Reconstruction Rate After Mastectomy. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70598-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Romics L, Chew BK, Weiler-Mithoff E, Doughty JC, Brown IM, Stallard S, Wilson CR, Mallon EA, George WD. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg 2012; 99:799-806. [PMID: 22367773 DOI: 10.1002/bjs.8704] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2012] [Indexed: 12/16/2022]
Abstract
BACKGROUND The oncological safety of skin-sparing mastectomy (SSM) followed by immediate breast reconstruction (IBR) is debated owing to a presumed compromise in the completeness of mastectomy. Current evidence is poor as it is based mostly on short-term follow-up data from highly selected patients. METHODS A prospectively maintained institutional database was searched to identify patients who underwent SSM and IBR between 1995 and 2000. A retrospective review of medical records was carried out, including only patients with ductal carcinoma in situ and invasive breast cancer. During this time all patients treated with mastectomy were offered IBR regardless of tumour stage. RESULTS Follow-up data from 253 consecutive patients with IBR were reviewed. Patients with incomplete follow-up data and those undergoing SSM for recurrent disease following previous lumpectomy were disregarded, leaving 207 for analysis. Offering IBR to all women requiring mastectomy resulted in a large proportion of patients with advanced disease. During a median follow-up of 119 months, 17 (8·2 per cent) locoregional, six (2·9 per cent) local and 22 (10·6 per cent) distant recurrences were detected; the overall recurrence rate was 39 (18·8 per cent). Overall recurrence rate was associated with axillary lymph node metastasis (P = 0·009), higher stage (P < 0·001) and higher tumour grade (P = 0·031). The breast cancer-specific survival rate was 90·8 per cent (19 of 207 women died from recurrence). CONCLUSION Based on these long-term follow-up data, SSM combined with IBR is an oncologically safe treatment option regardless of tumour stage.
Collapse
Affiliation(s)
- L Romics
- Department of Surgery, Victoria Infirmary, Southern General Hospital, Glasgow, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Chakrabarti M, Stallard S, Fitzgerald C, Obondo C, Weiler-Mithoff E, Doughty J, Romics L. P2-16-11: Role of Proper Patient Counselling in Combination with Effect of Socioeconomic Deprivation on the Rate of Immediate Breast Reconstruction after Mastectomy. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-16-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: current guidelines in the United Kingdom suggest that the possibility of breast reconstruction should be discussed with all patients prior to mastectomy. However, the majority of patients are still treated with mastectomy alone and no reconstruction is carried out. It has also been suggested that women from more deprived areas are less likely to undergo immediate breast reconstruction (IBR). We investigated potential pitfalls in patient counselling and consequent decision making contributing to present IBR rate in combination with the effect of socioeconomic deprivation.
Methods: data from 89 consecutive mastectomy patients was prospectively collected in a single centre in Glasgow between August 2010 and March 2011. Each patient was scored for deprivation based on The Scottish Index of Multiple Deprivation. The patients were then divided into two groups: high and low deprivation levels. Consultations about IR and patients’ acceptance of counselling were analysed. For statistical calculations Fischer's exact test was applied. Results: IBR was offered to 41 (46%) patients, but it was not to 42 (47%) (6 were excluded due to incomplete data). 25 patients accepted IBR, and of those 24 (27%) underwent IBR. 16 of 41 patients refused to undergo IBR due to lack of interest (10), not feeling ready for it (2), preference of delayed procedure (2) and fear of delaying adjuvant therapy (2). Of 42 patients whom IBR was not offered, only 10 were documented in the notes, while there was no reference for discussing reconstruction in 32 (36%) cases. Reasons for not even discussing reconstruction were the following: age (15), co-morbidities (18), locally advanced cancer (2), co-morbidities with age (5), and locally advanced cancer with age (2). As regards to socioeconomic deprivation; 44 (49%) patients were from deprived areas and 39 (44%) from affluent areas. 41 patients were offered IBR and of these 23 (26%) were from affluent areas compared to 18 (20%). Of the 42 patients who were not offered IR, 26 (29%) were from deprived while 16 (18%) from affluent areas (p<0.05). Of the 44 deprived patients, 18 were offered IBR but 26 were not. 15 of 25 patients, who accepted IBR, were from affluent areas. The 16 patients who refused IBR had equal distribution of deprivation.
Conclusions: while none of the reasons for not offering IBR represent absolute contraindication to IBR, decisions about refusal are based mostly on patients’ subjective intuitions. Further, a greater proportion of the patients who were not offered IBR were from more deprived areas, and it seems that patients from affluent areas are more likely to be offered IBR compared to ones from deprived areas. However, confounding factors such as co-morbidities may contribute to the above. We believe, therefore, that detailed counselling about reconstruction of each patient requiring mastectomy is necessary, which is likely to further increase IBR rate.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-16-11.
Collapse
Affiliation(s)
- M Chakrabarti
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - S Stallard
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - C Fitzgerald
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - C Obondo
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - E Weiler-Mithoff
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - J Doughty
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| | - L Romics
- 1Victoria Infirmary Glasgow; Glasgow Royal Infirmary; Western Infirmary Glasgow
| |
Collapse
|
17
|
Saldanha JD, Garrett RM, Snaddon L, Longmuir M, Bradshaw N, Watt C, George WD, Wilson CR, Doughty JC, Stallard S, Reid I, Murday V, Davidson R. Impact of national guidelines on family history breast cancer surveillance. Scott Med J 2011; 56:203-5. [PMID: 22089040 DOI: 10.1258/smj.2011.011158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The breast cancer risk of women already under family history surveillance was accurately assessed according to national guidelines in an attempt to rationalize the service. Women attending two breast units in Glasgow between November 2003 and February 2005 were included. One thousand and five women under annual surveillance were assessed and had their relatives diagnoses verified. Four hundred and ninety-seven women were at significantly increased risk and eligible for follow-up. Five hundred and eight (50%) women attending were not eligible for family history surveillance, and 498 (98%) of these women accepted discharge. In conclusion, national guidelines have helped to more clearly define women who should undergo surveillance. This avoids unnecessary and potentially harmful routine investigations, and the service has been improved.
Collapse
Affiliation(s)
- J D Saldanha
- Victoria Infirmary, Langside Road, Glasgow G42 9TY, Scotland, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Chakrabarti M, Fitzgerald K, Obondo C, Weiler-Mithoff E, Stallard S, Romics L. Effect of socioeconomic deprivation on the rate of immediate breast reconstruction after mastectomy. Eur J Surg Oncol 2011. [DOI: 10.1016/j.ejso.2011.08.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
19
|
Obondo CA, Fitzgerald K, Gray J, Chakarabharti M, Stallard S, Romics L. Pre-operative Ultrasound Staging of the Axilla in Breast Cancer - Repeat Audit Cycle. Eur J Surg Oncol 2011. [DOI: 10.1016/j.ejso.2011.08.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
20
|
Chakrabarti M, Fitzgerald K, Obondo C, Weiler-Mithoff E, Stallard S, Romics L. Role of proper patient counselling about immediate breast reconstruction after mastectomy. Eur J Surg Oncol 2011. [DOI: 10.1016/j.ejso.2011.08.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
21
|
Gray J, Glynn C, Stallard S. Pre-operative ultrasound staging of the axilla in breast cancer - a retrospective audit. Eur J Surg Oncol 2010. [DOI: 10.1016/j.ejso.2010.08.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
22
|
Marla S, Roxburgh P, Burton P, Stallard S, Mallon E, Canney P, Cooke T. HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3159
Background: Various trials have shown substantial benefits of addition of Trastuzumab (Herceptin®) to adjuvant chemotherapy in Early Breast Cancer (EBC). We analysed our breast cancer population to determine the incidence of HER2 positive Early Breast Cancers, the tumour demographics and the number of patients eligible for and receiving trastuzumab therapy in this group.
 Methods: Data for all patients diagnosed with EBC in 2006 was recorded prospectively in a database. Case notes were consulted where the HER2 positive patients, determined by a combination of IHC and FISH, had not received trastuzumab, to ascertain the reasons.
 Results: A total of 951 patients were diagnosed with Breast Cancer in 2006. 417 (43.9%) of these were screen-detected cancers.
 There were 123 (12.9%) HER2 positive newly diagnosed Breast Cancers of whom 117 were EBCs. The HER2 positivity rate in the screen detected cancers (n=417) was 9% and 17% in the symptomatic cancers (n=433).
 1. Demographics of the HER2 positive Early Breast Cancer Population:
 The median age at diagnosis was 61 yrs (range: 30-92).
 
 2. Fifty nine (50.4%) of the HER2 positive EBCs received trastuzumab therapy.
 
 Conclusions: The HER2 positivity rate is lower than that previously reported suggestive of changing demographics secondary to a high screen detected cancer population. A third of the HER2 positive tumours are screen detected. The percentage of ER positive, node negative and low grade tumours was higher than anticipated.
 Only 50% of HER 2 positive EBC patients received trastuzumab therapy. Of those who did not receive trastuzumab, the commonest reason was low risk status or age and co-morbidities precluded chemotherapy.
 HER 2 positivity alone confers high risk irrespective of pathological stage. Further trials are required to evaluate whether the substantial number of patients who are at present not eligible for trastuzumab therapy might also benefit.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3159.
Collapse
Affiliation(s)
- S Marla
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - P Roxburgh
- 2 Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - P Burton
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - S Stallard
- 4 Surgery, Victoria Infirmary, Glasgow, United Kingdom
| | - E Mallon
- 3 Pathology, Western Infirmary, Glasgow, United Kingdom
| | - P Canney
- 2 Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - T Cooke
- 1 Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
| |
Collapse
|
23
|
Forder A, Romics L, Ogston K, Stallard S, Cooke T, Mallon E, Weiller-Mithoff E. The oncological safety of axillary node clearance in the lateral decubitus position in patients with immediate ALD reconstructions. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70853-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
24
|
Saldanha J, Garret R, Longmuir M, Watt C, George D, Wilson C, Doughty J, Smith D, Stallard S, Davidson R. A multidisciplinary team approach to family history risk assessment reduced clinic attendance by half. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80059-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
25
|
Purushotham AD, McLatchie E, Young D, George WD, Stallard S, Doughty J, Brown DC, Farish C, Walker A, Millar K, Murray G. Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. Br J Surg 2002; 89:286-92. [PMID: 11872051 DOI: 10.1046/j.0007-1323.2001.02031.x] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Women undergoing surgery for primary breast cancer routinely have suction drains inserted deep to the wounds, which are removed approximately 6-8 days after operation, requiring a period of stay of that duration in hospital. The aim of this study was to perform a prospective randomized clinical trial to evaluate a new surgical technique of suturing flaps without wound drainage, combined with early discharge, in women undergoing surgery for breast cancer. METHODS A total of 375 patients undergoing surgery for breast cancer were randomized to conventional surgery or suturing of flaps with no drain. The main outcome measures were length of hospital stay, surgical morbidity, psychological morbidity and health economics. RESULTS Suturing of flaps and avoiding wound drainage in women undergoing surgery for breast cancer resulted in a significantly shorter hospital stay. Adopting this surgical technique with early discharge did not lead to any difference in surgical or psychological morbidity. Health economic benefits to the National Health Service resulted from saved bed days with no impact on community costs. CONCLUSION Wound drainage following surgery for breast cancer can be avoided, thereby facilitating early discharge with no associated increase in surgical or psychological morbidity.
Collapse
Affiliation(s)
- A D Purushotham
- Department of Surgery, Western Infirmary, University of Edinburgh, Edinburgh, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Stallard S. Menopausal status cannot be assessed in a significant number of breast cancer patients. Eur J Cancer 2002. [DOI: 10.1016/s0959-8049(02)80253-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Stallard S. Distance from the nipple is a factor predicting for local recurrence in patients with DCIS treated by wide local excision. Eur J Cancer 2002. [DOI: 10.1016/s0959-8049(02)80386-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Stallard S, Hole DA, Purushotham AD, Hiew LY, Mehanna H, Cordiner C, Dobson H, Mallon EA, George WD. Ductal carcinoma in situ of the breast -- among factors predicting for recurrence, distance from the nipple is important. Eur J Surg Oncol 2001; 27:373-7. [PMID: 11417983 DOI: 10.1053/ejso.2001.1123] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AIMS To assess local and systemic recurrence rates and factors predicting for recurrence in patients treated for ductal carcinoma of the breast (DCIS). METHODS Patients with DCIS treated between January 1986 and January 1997 were identified. All pathology specimens were reviewed. DCIS type, lesion size, nuclear grade and margin clearance were assessed. Mammograms were reviewed and mammographic patterns, size, type of lesion and distance from the nipple were measured. Treatments and subsequent outcomes were established by case note review. Factors predicting for recurrence were analysed by both univariant and multivariant analysis. RESULTS Of the 220 patients, 153 (70%) had breast-conserving surgery. Sixty-seven (30%) had a mastectomy. Ninety-seven patients had adjuvant therapy of which 22 had radiotherapy alone, 54 had tamoxifen alone and 21 had radiotherapy and tamoxifen. Following mastectomy, two patients developed axillary recurrences. Following breast-conserving surgery 20 (13%) patients developed local recurrences, of which one developed systemic disease and died from breast cancer. CONCLUSIONS Mammographic nipple to lesion distance of <40 mm and high/intermediate nuclear grade were the only factors found to increase the likelihood of recurrence.
Collapse
Affiliation(s)
- S Stallard
- University Department of Surgery, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
This study investigates post-operative photographic assessment in determining the cosmetic outcome of 74 breast cancer patients who underwent a breast lumpectomy and radiotherapy. Using 10 of these patients picked at random, comparison was made between a conventional photographic print, a print produced from a digital image, and a digital image viewed on a computer screen in terms of personal preference for clinical assessment. The cosmetic outcome scores obtained on the basis of these images were compared with cosmetic outcome scores obtained by direct observation both by the clinician and by the patient. In the analysis of image preference, conventional prints scored highest, but each of the image types was considered to be acceptable for assessing breast cosmesis. Statistical analysis of the cosmetic outcome scores proved that there was a significant correlation between the scores obtained from the images and the scores obtained by direct observation both by the clinician and by the patient.
Collapse
Affiliation(s)
- C Eadie
- Department of Medical Illustration, Western Infirmary, Glasgow, Scotland.
| | | | | |
Collapse
|
30
|
Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA, Hole D. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ 2000; 320:348-9. [PMID: 10657329 PMCID: PMC27281 DOI: 10.1136/bmj.320.7231.348] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- S Stallard
- University Department of Surgery, North Glasgow Hospitals University NHS Trust, Glasgow G11 6NT
| | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
AIM The use of hormone replacement therapy (HRT) can lead to various changes on the mammogram including increasing density. The object of this study was to assess the effect of HRT on the sensitivity of mammographic screening by comparing HRT usage in women with screen detected breast cancers with HRT usage at the time of screening in women presenting with interval cancers. METHODS The West of Scotland Breast Screening Programme serves a population of 180,000 women aged 50-64 years old. Between May 1988 and December 1995, 1461 breast cancers were detected by the screening programme in 1441 women over the age of 50 and 372 interval breast cancers presented in 371 women screened between these dates. HRT usage at the time of screening was noted with details of age, postcode and the time between screening and diagnosis in the case of the women with interval cancers. RESULTS Among women under 65 years old, screened between 1988-1993, 12.3% of women with screen detected cancers and 22.2% of women with interval cancers were using HRT (P<0.001). Further analysis demonstrates that interval cancer rate is related to age as well as HRT use. After adjusting for age at time of screening, deprivation category and year of screening, the relative risk of a woman using HRT having an interval cancer compared with that of a woman not using HRT is 1.79. The relative risk of an interval cancer arising in the first year after screening for a woman on HRT is 2.27. CONCLUSION The use of HRT and being of an age below 60 years are both risk factors for presenting with an interval cancer after mammographic breast screening. Our results indicate that the use of HRT leads to a decrease in the sensitivity of mammographic screening.
Collapse
Affiliation(s)
- J C Litherland
- West of Scotland Breast Screening Service, Glasgow, Scotland, UK
| | | | | | | |
Collapse
|
32
|
Hiew L, Stallard S, Purushotham A, Mehana H, Cordiner C, Dobson H, Mallon E, George W. Ductal carcinoma in situ: Factors affecting recurrence. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80022-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Stallard S, Cordiner C, Litherland J. 0-57. The effect of hormone replacement therapy on the sensitivity of mammographic screening. Breast 1997. [DOI: 10.1016/s0960-9776(97)90638-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
34
|
Doughty J, Mallon E, Stallard S, George W. 0-87. Assessing the adequacy of mastectomy by flap biopsies. Breast 1997. [DOI: 10.1016/s0960-9776(97)90668-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
35
|
Goldberg JA, Scott RN, Davidson PM, Murray GD, Stallard S, George WD, Maguire GP. Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol 1992; 18:327-31. [PMID: 1521623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
In this prospective study, the psychological morbidity associated with the treatment of breast cancer was assessed. The study population comprised all patients referred to one centre with a recently diagnosed breast lump, who were to undergo surgery. Psychological morbidity was assessed preoperatively and at 6 and 12 months postoperatively by modified Rotterdam Symptom Checklist. Three hundred and twenty patients completed all three questionnaires: 93 women undergoing mastectomy, 73 women having conservation therapy for breast cancer and 156 women having biopsy for benign breast disease. Patients with a breast malignancy smaller than 4 cm in diameter were treated by lumpectomy and radiotherapy, anti-oestrogen therapy or chemotherapy alone or in combination. Psychological morbidity among patients with malignant disease was significantly greater than that seen in the group with benign disease. Among cancer patients, a significant decrease in anxiety and depression occurred during the year following surgery. The study failed to demonstrate any psychological advantage associated with breast conservation.
Collapse
|
36
|
Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991; 9:295-304. [PMID: 1988576 DOI: 10.1200/jco.1991.9.2.295] [Citation(s) in RCA: 84] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Two hundred eleven patients with advanced breast cancer were randomized to receive either epirubicin (E) 50 mg/m2 and prednisolone (LEP) or E 100 mg/m2 and prednisolone (HEP). The intended treatment consisted of 16 courses of LEP or eight courses of HEP given at 3-weekly intervals. Reasons for stopping treatment early included progressive disease, stable disease without symptomatic improvement, or severe toxicity deemed intolerable by either the patient or physician. Toxicity was recorded at 3-weekly and response at 9-weekly intervals using the World Health Organization (WHO) criteria of response and toxicity. Two hundred nine patients were eligible for analysis, 98% of whom have been followed for more than a year. One hundred four patients received LEP and 105 HEP. Significantly worse myelosuppression, alopecia, nausea and vomiting, and mucositis were seen in the high-dose arm (P less than or equal to .001). More patients in the LEP arm stopped treatment before the fourth course than in the HEP arm, and the commonest reason for stopping was progressive disease. A similar median number of courses was given in each arm. There was a significantly higher response in the HEP arm (HEP - complete response [CR] + partial response [PR] = 41%, LEP - CR + PR = 23%). Despite this, no statistically significant differences was seen in overall survival or progression-free interval. The median survival for HEP and LEP was 44 and 46 weeks, respectively.
Collapse
Affiliation(s)
- T Habeshaw
- Beatson Oncology Centre, Western Infirmary, Glasgow, Scotland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Ischaemia of the greater curve of the stomach is a possible complication of splenectomy. We describe a case in which ischaemia resulted in necrosis and perforation of the stomach in a patient after splenectomy for massive splenomegaly. There are no previously reported cases in the literature.
Collapse
Affiliation(s)
- S Stallard
- Department of Surgery, Western Infirmary, Glasgow
| | | |
Collapse
|
38
|
Abstract
Increased expression of the mdr1 gene, encoding the 175 kDa P-glycoprotein, and the gst-pi gene, encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin. In this present study we have measured RNA levels of mdr1 and gst-pi in primary human breast tumour biopsies prior to chemotherapy and from tumours which have different inherent responses to doxorubicin treatment, including colon, head and neck squamous cell carcinomas and myeloid leukaemias. Detectable levels of mdr1 mRNA was observed in 25 out of 49 breast tumours, with up to a 100-fold range in expression. A narrower range of gst-pi expression has also been observed in these tumours. Chemosensitivity of cells grown in short-term culture from some of the breast tumours has been measured by an in vitro colony forming assay in the presence of doxorubicin. Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID50) with RNA levels showed that the tumours with high mdr1 expression had high ID50, while the more sensitive explants had low mdr1 expression. These results support a role for mdr1 gene expression in determining the response of human breast cancer cells to chemotherapy.
Collapse
Affiliation(s)
- W N Keith
- CRC Department of Medical Oncology, Glasgow, UK
| | | | | |
Collapse
|
39
|
Stallard S, Morrison JG, George WD, Kaye SB. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol 1990; 25:286-90. [PMID: 2295114 DOI: 10.1007/bf00684887] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Response to cytotoxic agents is assumed to be related to the concentration of drug achieved within tumour tissue. It is also often assumed that, given similar tissue concentrations of drug, normal tissues are less responsive to the same cytotoxic agents. This can partly be explained by the number of cells in normal tissues that are differentiated. These non dividing cells, in a stable testing phase of the cell cycle (G0) are less susceptible to cytotoxic damage. Little is actually known about the relationship between tumour drug concentrations and those in the tissue of the tumour-bearing organ. In this study, we compared doxorubicin concentrations in paired samples of tumour and normal breast tissue from 17 previously untreated women undergoing mastectomy. The relative cellularities of both specimens were estimated by measuring their DNA content. There was wide variation in intra-tumoural doxorubicin concentrations (range, 220-1,590 ng/g). Normal tissue also showed marked inter-patient variation (range, 81-1,000 ng/g). For a single patient the tumour drug concentrations were significantly higher than those in normal breast tissue (P less than 0.05), and tumour: normal tissue ratios ranged from 1.27 to 8.30. Where doxorubicin concentration was expressed in terms of the relative cellularity of the tissues, there was no significant difference between, drug concentrations in the tumour and those in normal breast tissue (tumour: normal ratios, 1.1:1.8). There was a significant correlation (r = 0.76, P less than 0.05) between peak serum values and tumour concentrations of drug. No correlation was found between drug concentrations achieved and the histological grade or oestrogen receptor status of the breast cancer.
Collapse
Affiliation(s)
- S Stallard
- CRC Department of Medical Oncology, University of Glasgow, U.K
| | | | | | | |
Collapse
|
40
|
Abstract
A prospective study has been performed to measure the incidence of postoperative urinary retention in 280 general surgical patients. Eighteen patients (6 per cent) were catheterized after a range of operations under general anaesthesia. There was no statistical difference in the retention rate between men and women. Increasing age did not predispose to retention of urine. Of 72 patients who had either herniorrhaphy, haemorrhoidectomy or testicular operations, only 1 was catheterized, whereas 16 (23 per cent) of 70 patients undergoing laparotomy were catheterized. Most of these laparotomy patients had upper abdominal procedures carried out. Those having lower abdominal operations were usually catheterized pre-operatively and were excluded from the study. There was a significantly higher incidence of retention among patients who had long anaesthetics (greater than 60 min). There was also a significantly higher incidence of retention among those who were ventilated, relaxed and reversed by atropine and neostigmine. Of those 193 patients who had opiate analgesia, 15 (8 per cent) developed retention of urine, compared with 3 (3 per cent) of the 87 patients who had non-opiate analgesia. There was a significantly higher retention rate among the patients who had opiate analgesia by intravenous infusion compared with those who had opiates by intramuscular bolus injection; 7 patients had painful and 11 had painless retention. This study suggests that postoperative retention of urine is a result more commonly of diminished awareness of bladder sensation, than of factors such as anxiety or local pain.
Collapse
Affiliation(s)
- S Stallard
- Bangour General Hospital, Broxburn, West Lothian, UK
| | | |
Collapse
|
41
|
|
42
|
Liu YK, Stallard S, Koo V, Dannaher CL. Serum inhibitor activity of granulocyte-macrophage colony formation in patients with cancer. Cancer Res 1979; 39:1640-4. [PMID: 311687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The serum inhibitor activities of granulocyte-macrophage colony formation were evaluated by the in vitro culture technique in 60 patients with cancer and control subjects including 24 normal adults and 27 patients with a variety of nonneoplastic disorders. The inhibitor activity in cancer patients (mean, 59%) was significantly higher (p less than 0.001) than was that in normal adults (mean, 31%) and patients with nonneoplastic diseases (mean 36%). There was no difference in the inhibitor activity between the latter two groups of subjects. There was no correlation between the serum inhibitor activity in cancer patients and the histological type or primary site of tumor, the estimated duration of extent of disease, and serum albumin levels. Preliminary observations indicated that the inhibitor activity may be associated with serum lipoproteins. There was no significant difference in serum colony-stimulating activity among cancer patients, normal subjects, and patients with nonneoplastic diseases.
Collapse
|
43
|
Stallard S, Orpin PD. A short trial automatic cell-washing centrifuges. Med Lab Technol 1971; 28:35-7. [PMID: 5555283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|